Evidence map›Paper›PMID 34371692›Full record

ArticlePharmaceutics2021

Antitumor Activity against Human Colorectal Adenocarcinoma of Silver Nanoparticles: Influence of [Ag]/[PVP] Ratio.

Omar Ulises Cruz-Ramírez, Lucía Margarita Valenzuela-Salas, Alberto Blanco-Salazar, José Antonio Rodríguez-Arenas, Paris A Mier-Maldonado, Juan Carlos García-Ramos, Nina Bogdanchikova, Alexey Pestryakov, Yanis Toledano-Magaña

Abstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Treatment with ArgovitNanomaterials (Basel, Switzerland) · 2021
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Omar Ulises Cruz-RamírezCentro de Nanociencias y Nanotecnología, Universidad Nacional Autónoma de México, Ensenada 22860, Mexico.
Lucía Margarita Valenzuela-SalasFacultad de Ciencias de la Salud Unidad Valle de las Palmas, Universidad Autónoma de Baja California, Tijuana 22260, Mexico.ORCID 0000-0002-2226-0431
Alberto Blanco-SalazarPrograma de Maestría y Doctorado en Ciencias e Ingeniería, Facultad de Ciencias, Universidad Autónoma de Baja California, Ensenada 22860, Mexico.ORCID 0000-0003-2401-6237
José Antonio Rodríguez-ArenasPrograma de Maestría y Doctorado en Ciencias e Ingeniería, Facultad de Ciencias, Universidad Autónoma de Baja California, Ensenada 22860, Mexico.ORCID 0000-0001-8070-702X
Paris A Mier-MaldonadoFacultad de Ciencias de la Salud Unidad Valle de las Palmas, Universidad Autónoma de Baja California, Tijuana 22260, Mexico.
Juan Carlos García-RamosEscuela de Ciencias de la Salud Unidad Valle Dorado, Universidad Autónoma de Baja California, Ensenada 22890, Mexico.ORCID 0000-0001-9861-2467
Nina BogdanchikovaCentro de Nanociencias y Nanotecnología, Universidad Nacional Autónoma de México, Ensenada 22860, Mexico.ORCID 0000-0003-0929-3535
Alexey PestryakovResearch School of Chemistry & Applied Biomedical Sciences, National Research Tomsk Polytechnic University, 634050 Tomsk, Russia.ORCID 0000-0002-9034-4733
Yanis Toledano-MagañaEscuela de Ciencias de la Salud Unidad Valle Dorado, Universidad Autónoma de Baja California, Ensenada 22890, Mexico.

Funding

OSTEOGENESIS: DEVELOPMENT, MODULATION, AND AGINGR01AG002577 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI NIMNI, MARCEL E · 1985 to 1986
–
OSTEOGENESIS: DEVELOPMENT, MODULATION, AND AGINGR37AG002577 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI NIMNI, MARCEL E · 1988 to 1997
–
Secretaría de Educación Pública PRODEP UABC-PTC-819Secretaría de Educación Pública PRODEP UABC-PTC-869Tomsk Polytechnic University Priority 2030Universidad Autónoma de Baja California SICASPI-349/2560Universidad Autónoma de Baja California SICASPI-351/2420Universidad Autónoma de Baja California SICASPI-439-2577
6 · The paper itself

Abstract

Silver nanoparticles (AgNPs) not only have shown remarkable results as antimicrobial and antiviral agents but also as antitumor agents. This work reports the complete characterization of five polyvinylpyrrolidone-coated AgNP (PVP-AgNP) formulations, their cytotoxic activity against human colon tumor cells (HCT-15), their cytotoxic effect on primary mouse cultures, and their lethal dose on BALB/c mice. The evaluated AgNP formulations have a composition within the ranges Ag: 1.14-1.32%

Indexed as

AgNPsantitumor activitycolon cancercytotoxic selectivityGSH classificationHCT-15[metal]/[coating agent] ratiotherapeutic index

Identifiers

PMID34371692
PMCPMC8308985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.